Results 21 to 30 of about 38,450 (306)

Cancer immunomodulation using bispecific aptamers

Molecular Therapy: Nucleic Acids, 2022
Evasion of immune destruction is a major hallmark of cancer. Recent US Food and Drug Administration (FDA) approvals of various immunomodulating therapies underline the important role that reprogramming the immune system can play in combating this disease.
Brian J. Thomas, David Porciani, Donald H. Burke   +2 more
doaj   +1 more source

THE ALBUMIN-BINDING DOMAIN AS A SCAFFOLD FOR PROTEIN ENGINEERING

Computational and Structural Biotechnology Journal, 2013
The albumin-binding domain is a small, three-helical protein domain found in various surface proteins expressed by gram-positive bacteria. Albumin binding is important in bacterial pathogenesis and several homologous domains have been identified.
Johan Nilvebrant, Sophia Hober
doaj   +1 more source

The Development of Bispecific Hexavalent Antibodies as a Novel Class of DOCK-AND-LOCKTM (DNLTM) Complexes

Antibodies, 2013
The DOCK-AND-LOCKTM (DNLTM) method provides a modular approach to develop multivalent, multifunctional complexes of defined structures, of which bispecific hexavalent antibodies (bsHexAbs) are prominent examples with potential applications in targeted ...
Chien-Hsing Chang, Edmund A. Rossi, Yang Wang, Thomas M. Cardillo, David M. Goldenberg   +4 more
doaj   +1 more source

CAR T-Cell Therapy Predictive Response Markers in Diffuse Large B-Cell Lymphoma and Therapeutic Options After CART19 Failure

Frontiers in Immunology, 2022
Immunotherapy with T cells genetically modified with chimeric antigen receptors (CARs) has shown significant clinical efficacy in patients with relapsed/refractory B-cell lymphoma.
Ana Carolina Caballero, Ana Carolina Caballero, Ana Carolina Caballero, Ana Carolina Caballero, Laura Escribà-Garcia, Laura Escribà-Garcia, Laura Escribà-Garcia, Carmen Alvarez-Fernández, Carmen Alvarez-Fernández, Carmen Alvarez-Fernández, Javier Briones, Javier Briones, Javier Briones, Javier Briones   +13 more
doaj   +1 more source

Conformation-selective rather than avidity-based binding to tumor associated antigen derived peptide-MHC enables targeting of WT1-pMHC low expressing cancer cells by anti-WT1-pMHC/CD3 T cell engagers

Frontiers in Immunology, 2023
T cell engagers, a category of T cell-retargeting immunotherapy, are rapidly transforming clinical cancer care. However, the lack of tumor-specific targets poses a significant roadblock for broad adaptation of this therapeutic modality in many ...
Even Walseng, Bo Wang, Chunning Yang, Pooja Patel, Chihao Zhao, Hanzhi Zhang, Peng Zhao, Yariv Mazor   +7 more
doaj   +1 more source

Bispecific Antibodies: A Novel Approach for the Treatment of Solid Tumors

Pharmaceutics, 2022
Advancement in sequencing technologies allows for the identification of molecular pathways involved in tumor progression and treatment resistance.
Luigi Liguori, Giovanna Polcaro, Annunziata Nigro, Valeria Conti, Carmine Sellitto, Francesco Perri, Alessandro Ottaiano, Marco Cascella, Pio Zeppa, Alessandro Caputo, Stefano Pepe, Francesco Sabbatino   +11 more
doaj   +1 more source

Alternative Scaffolds as Bispecific Antibody Mimetics

, 2011
The use of non-immunoglobulin-based protein scaffolds for engineering of specific recognition was first described some 15 years ago and has matured as a discipline in parallel with the rapidly expanding monoclonal antibody field. As bispecific antibodies
Frejd, Fredrik, Löfblom, John,, John Löfblom, Fredrik Y. Frejd   +3 more
core   +1 more source

Novel Bispecific Aptamer Enhances Immune Cytotoxicity Against MUC1-Positive Tumor Cells by MUC1-CD16 Dual Targeting

Molecules, 2019
A promising strategy in cancer immunotherapy is the employment of a bispecific agent that can bind with both tumor markers and immunocytes for recruitment of lymphocytes to tumor sites and enhancement of anticancer immune reactions.
Zhaoyi Li, Yan Hu, Yacong An, Jinhong Duan, Xundou Li, Xian-Da Yang   +5 more
doaj   +1 more source

Efficacy of rFVIIIFc versus Emicizumab for the Treatment of Patients with Hemophilia A without Inhibitors: Matching-Adjusted Indirect Comparison of A-LONG and HAVEN Trials

Journal of Blood Medicine, 2021
Robert Klamroth,1 Piotr Wojciechowski,2 Samuel Aballéa,3 Françoise Diamand,4 Zalmai Hakimi,5 Jameel Nazir,5 Lydia Abad-Franch,6 Stefan Lethagen,7 Elena Santagostino,8 Michael D Tarantino9 1Department of Internal Medicine, Hemophilia ...
Klamroth R, Wojciechowski P, Aballéa S, Diamand F, Hakimi Z, Nazir J, Abad-Franch L, Lethagen S, Santagostino E, Tarantino MD   +9 more
doaj  

Perspective: Designing T-Cell Engagers With Better Therapeutic Windows

Frontiers in Oncology, 2020
This perspective highlights the history and challenges of developing CD3-based bispecific T-cell engagers (TCEs) as cancer therapeutics as well as considerations and potential strategies for designing the next generation TCE molecules.
Omid Vafa, Nathan D. Trinklein
doaj   +1 more source